Clinical efficacy of <italic style="font-style: italic">Mafu Yishen Decoction</italic> in treating intermediate-and high-risk membranous nephropathy

HUANG Shuxian; RUI Hongliang; DAI Haoran; ZHAO Qihan; ZHANG Naiqian; WANG Qing; DING Qian; LIU Baoli

doi:10.16025/j.1674-1307.2025.02.005

您当前的位置：

首页 >

文章列表页 >

Clinical efficacy of Mafu Yishen Decoction in treating intermediate-and high-risk membranous nephropathy

更新时间：2025-03-19

- Clinical efficacy of Mafu Yishen Decoction in treating intermediate-and high-risk membranous nephropathy
- Beijing Journal of Traditional Chinese Medicine Vol. 44, Issue 2, Pages: 137-141(2025)
- 作者机构：
  
  1.北京中医药大学，北京 100029
  2.北京市中医药研究所，北京 100010
  3.北京中医医院顺义医院肾病科，北京 101300
  4.首都医科大学附属北京中医医院，北京 100010
  5.澳门科技大学药学院中药质量研究国家重点实验室，澳门 999078
  6.首都医科大学附属北京中医医院肾病及风湿免疫诊疗中心，北京 100010
- 作者简介：
- 基金信息：
- DOI：10.16025/j.1674-1307.2025.02.005
  CLC：
- Received：17 December 2024，
  
  Published：25 February 2025
- 稿件说明：
移动端阅览
黄淑贤，芮宏亮，戴浩然，等.麻附益肾方治疗中、高风险膜性肾病的临床疗效观察［J］.北京中医药，2025，44（2）：137-141.

HUANG Shuxian,RUI Hongliang,DAI Haoran,et al.Clinical efficacy of Mafu Yishen Decoction in treating intermediate-and high-risk membranous nephropathy[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(02):137-141.
黄淑贤，芮宏亮，戴浩然，等.麻附益肾方治疗中、高风险膜性肾病的临床疗效观察［J］.北京中医药，2025，44（2）：137-141. DOI： 10.16025/j.1674-1307.2025.02.005.

HUANG Shuxian,RUI Hongliang,DAI Haoran,et al.Clinical efficacy of Mafu Yishen Decoction in treating intermediate-and high-risk membranous nephropathy[J]. Beijing Journal of Traditional Chinese Medicine,2025,44(02):137-141. DOI： 10.16025/j.1674-1307.2025.02.005.

摘要

目的

通过真实世界研究，评估麻附益肾方治疗中、高风险膜性肾病（MN）外寒内虚、寒凝癥积证的疗效与安全性。

方法

收集2016—2022年间在北京中医医院肾病科接受麻附益肾方治疗的中、高风险MN患者的资料，研究的主要结局指标为患者达到完全或部分缓解标准的复合指标；次要结局指标包括：24 h尿蛋白定量（UTP）、血清白蛋白（ALB）、血肌酐（SCr）、肾小球滤过率（eGFR）及肾病综合征的其他表现。

结果

①共纳入152例MN患者，其中中风险36例，高风险116例，治疗时间为48.0（34.8，63.6）个月。②治疗后，75.7%（115/152）患者达到临床缓解，其中29.6%为完全缓解，46.1%为部分缓解。治疗第12、24、36、48个月的累积缓解率分别为30.9%、55.9%、66.4%、73.0%。③随访期间10.4%的患者出现复发，从缓

解到复发的时间为14.5（7.5，22.5）个月。④治疗后，MN患者的血清ALB由26.0（22.4，30.2）g/L上升至40.2（34.6，44.1）g/L（

0.01），24 h UTP由7.5（5.0，10.2）g下降到1.1（0.1，3.9）g（

0.01），血脂水平降低（

0.01）。⑤麻附益肾方治疗过程中，未观察到明显的不良反应。

结论

麻附益肾方能有效改善MN外寒内虚、寒凝癥积证患者的临床症状和肾病综合征状态，且复发率低。

Abstract

Objective

To evaluate the efficacy and safety of

Mafu Yishen Decoction

in the treatment of intermediate- and high-risk membranous nephropathy （MN） with external cold and internal deficiency， cold coagulation， and stasis accumulation syndrome through a real-world study.

Methods

Clinical data were collected from intermediate- and high-risk MN patients who received

Mafu Yishen Decoction

treatment at the Department of Nephrology， Beijing Hospital of Traditional Chinese Medicine， between 2016 and 2022. The primary outcome was a composite endpoint of complete or partial remission. Secondary outcomes included 24-hour urine protein quantification （UTP）， serum albumin （ALB）， serum creatinine （SCr）， estimated glomerular filtration rate （eGFR）， and other clinical manifestations of nephrotic syndrome.

Results

①A total of 152 MN patients were included， comprising 36 with intermediate risk and 116 with high risk. The median treatment duration was 48.0 （34.8，63.6） months.② After

Mafu Yishen Decoction

treatment， 75.7% （115/152） of patients achieved clinical remission， including 29.6% with complete remission and 46.1% with partial remission. The cumulative remission rates at 12， 24， 36， and 48 months were 30.9%， 55.9%， 66.4%， and 73.0%， respectively.③ Relapse occurred in 10.4% （12/115） of patients during follow-up； the time from remission to relapse was 14.5 （7.5，22.5） months. ④ After treatment， serum ALB increased from 26.0 （22.4，30.2） g/L to 40.2 （34.6，44.1） g/L （

0.01）， 24-hour UTP decrea

sed from 7.5 （5.0，10.2） g to 1.1 （0.1，3.9） g （

0.01）， and blood lipid levels significantly decreased （

0.01）.⑤ No significant adverse reactions were observed during

Mafu Yishen Decoction

treatment.

Conclusion

MaFu YiShen Decoction

can effectively improve the clinical symptoms and nephrotic syndrome status of patients with MN

yang

deficiency and symptomatic syndrome， with high safety and low recurrence rate. This therapy has the value of popularisation and application in clinical practice.

关键词

Keywords

references

XU X , WANG G , CHEN N , et al . Long-term exposure to air pollution and increased risk of membranous nephropathy in China [J ] . J Am Soc Nephrol , 2016 , 27 ( 12 ): 3739 - 3746 .

RONCO P , BECK L , DEBIEC H , et al . Membranous nephropathy [J ] . Nat Rev Dis Primers , 2021 , 7 ( 1 ): 69 .

HU R , QUAN S , WANG Y , et al . Spectrum of biopsy proven renal diseases in central China:a 10-year retrospective study based on 34 630 cases [J ] . Sci Rep , 2020 , 10 ( 1 ): 10994 .

ALSHARHAN L , BECK LH . Membranous nephropathy: core curriculum 2021 [J ] . Am J Kidney Dis , 2021 , 77 ( 3 ): 440 - 453 .

刘宝利 , 钟逸斐 , 刘伟敬 , 等 . 中医药临床优势病种探讨：膜性肾病 [J ] . 中国实验方剂学杂志 , 2021 , 27 ( 16 ): 185 - 190 .

赵启涵 , 戴浩然 , 姜韩雪 , 等 . 基于脏腑风湿论构建原发性膜性肾病态靶辨治体系 [J ] . 中医杂志 , 2023 , 64 ( 8 ): 774 - 778 .

ZHANG N , JIANG H , DAI H , et al . Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy:a multicenter prospective trial [J ] . Ren Fail , 2024 , 46 ( 1 ): 2320834 .

王海燕，赵明辉主编. 肾脏病学（上） [M ] . 4版 . 北京：人民卫生出版社 , 2020 . 12 ： 875 - 876 .

周仲瑛主编. 中医内科学 [M ] . 北京：中国中医药出版社 , 2003 ： 329 - 339 .

Kidney Disease : Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group . KDIGO 2021 clinical practice guideline for the management of glomerular diseases [J ] . Kidney Int , 2021 , 100 ( 4 ): 1 - 276 .

叶晓滨 . 麻黄常用药对化学成分与药理作用的研究进展 [J ] . 中医研究 , 2021 , 34 ( 3 ): 57 - 62 .

史攀博 , 李亨达 , 薛宁 , 等 . 附子药理、毒理及解毒机制研究述评 [J ] . 中医学报 , 2023 , 38 ( 11 ): 2347 - 2353 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Traditional Chinese medicine treatment of idiopathic pulmonary fibrosis based on NLRP3 inflammasome: a review

Connotation of TCM prevention and treatment of type 2 diabetes mellitus panangiopathy based on the theory of "latent evil blocking collaterals"

Portrait analysis of 12 593 gastric cancer patients treated with traditional Chinese medicine

Study on the efficacy of sequential Chinese medicine therapy in patients with non-muscle-invasive bladder cancer

Experience of treating membranous nephropathy by the method of balancing based on the theory of unbalanced kidney Qi

Related Author

KE Jia

YANG Yi

HE Cong

YANG Zhenyu

ZUO Wanzhao

JIANG Cheng

LYU Anqi

ZHUANG Xin

Related Institution

College of Traditional Chinese Medicine（TCM），Hubei University of Chinese Medicine

Hubei Provincial Hospital of TCM/Hubei Shizhen Laboratory/Affiliated Hospital of Hubei University of Chinese Medicine

Department of Scientific Research， Shandong University of Traditional Chinese Medicine， Ji'nan

Center of Treatment and Rehabilitation， The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine， Ji'nan

Department of Cardiology， Affiliated Hospital of Shandong University of Traditional Chinese Medicine， Ji'nan

⁰

Clinical efficacy of Mafu Yishen Decoction in treating intermediate-and high-risk membranous nephropathy

DOI：10.16025/j.1674-1307.2025.02.005

摘要

Abstract

关键词

Keywords

references